Showing 16,401 - 16,420 results of 105,386 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( e ((fold decrease) OR (point decrease)) ))', query time: 1.26s Refine Results
  1. 16401

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
  2. 16402

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
  3. 16403

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
  4. 16404

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
  5. 16405

    Supplementary Material for: Somatic variants and exon-level copy number changes in five hyperplastic-stage oral leukoplakias. by Anne A. (13992672)

    Published 2023
    “…Oral leukoplakia (OL), an oral potentially malignant disorder begins with a hyperplastic/hyperkeratotic stage at which no genome-scale somatic single nucleotide variant profiles have been described so far. …”
  6. 16406
  7. 16407
  8. 16408
  9. 16409
  10. 16410

    DataSheet_1_Zerumbone Modulates α2A-Adrenergic, TRPV1, and NMDA NR2B Receptors Plasticity in CCI-Induced Neuropathic Pain In Vivo and LPS-Induced SH-SY5Y Neuroblastoma In Vitro Mod... by Jasmine Siew Min Chia (8524626)

    Published 2020
    “…Zerumbone treatment markedly decreased the expression of α<sub>2A</sub>-adrenoceptor, while an up-regulation was observed of NMDA NR2B receptors. …”
  11. 16411

    Data_Sheet_1_Effectiveness of a program to lower unwanted media screens among 2–5-year-old children: a randomized controlled trial.docx by Nimran Kaur (11008865)

    Published 2024
    “…In the post-intervention assessment, 161 and 166 families continued while, at the follow-up assessment, 154 and 147 were in the intervention and control arm, respectively. The mean difference in ST on a typical day [27.7 min, 95% Confidence Interval (CI) 5.1, 50.3] at the post-intervention assessment significantly (p < 0.05) decreased in the intervention (102.6 ± 98.5 min) arm as compared with the control (130.3 ± 112.8 min) arm. …”
  12. 16412

    Data_Sheet_1_Effectiveness of a program to lower unwanted media screens among 2–5-year-old children: a randomized controlled trial.docx by Nimran Kaur (11008865)

    Published 2024
    “…In the post-intervention assessment, 161 and 166 families continued while, at the follow-up assessment, 154 and 147 were in the intervention and control arm, respectively. The mean difference in ST on a typical day [27.7 min, 95% Confidence Interval (CI) 5.1, 50.3] at the post-intervention assessment significantly (p < 0.05) decreased in the intervention (102.6 ± 98.5 min) arm as compared with the control (130.3 ± 112.8 min) arm. …”
  13. 16413
  14. 16414
  15. 16415
  16. 16416
  17. 16417
  18. 16418

    Early mobilization of critically ill patients in the intensive care unit: A systematic review and meta-analysis by Lan Zhang (90951)

    Published 2019
    “…Early mobilization decreased the incidence of ICU-acquired weakness (ICU-AW) at hospital discharge (three studies, 190 patients, relative risk (RR): 0.60, 95% confidence interval (CI) [0.40, 0.90]; <i>p</i> = 0.013, <i>I</i><sup><i>2</i></sup> = 0.0%), increased the number of patients who were able to stand (one study, 50 patients, 90% vs. 62%, <i>p</i> = 0.02), increased the number of ventilator-free days (six studies, 745 patients, standardized mean difference (SMD): 0.17, 95% CI [0.02, 0.31]; <i>p</i> = 0.023, <i>I</i><sup><i>2</i></sup> = 35.5%) during hospitalization, increased the distance the patient was able to walk unassisted (one study, 104 patients, 33.4 (0–91.4) meters vs. 0 (0–30.4) meters, <i>p</i> = 0.004) at hospital discharge, and increased the discharged-to-home rate (seven studies, 793 patients, RR: 1.16, 95% CI [1.00, 1.34]; <i>p</i> = 0.046). …”
  19. 16419
  20. 16420

    Image_5_T2DM may exert a protective effect against digestive system tumors in East Asian populations: a Mendelian randomization analysis.tif by Ni An (511459)

    Published 2024
    “…</p>Conclusion<p>T2DM is associated with a reduced risk of esophageal, gastric and colorectal cancer and hepatocellular carcinoma in East Asian populations. …”